ADM commits $25 million equity investment in Rennovia

Published on February 11, 2014 at 12:18 PM · No Comments

Archer Daniels Midland Company (NYSE: ADM) and Rennovia, Inc. announced today that ADM has committed to a $25 million equity investment in the privately held company, which develops catalysts and processes for the cost-advantaged production of chemical products from renewable feedstocks.

"This investment is part of ADM's ongoing efforts to enhance returns by strengthening our portfolio of higher-margin products," said Kevin Moore, ADM vice president, Renewable Chemicals. "There is significant and growing demand for chemical products made from renewable feedstocks. We are impressed with the technology Rennovia is developing, and look forward to the opportunity for its products to join our current portfolio of renewable chemicals—like propylene glycol and ethylene glycol—as they offer increased access to attractive end markets in nylons and other materials."

"We are committed to continuing to identify novel technologies that provide high yields and low conversion costs," said Todd Werpy, ADM senior vice president, Research and Development. "We believe that the new technologies being developed by Rennovia, coupled with ADM's strength in manufacturing, will help us to deliver competitive products that complement our growing portfolio."

"We are delighted to have the support of ADM as a strategic financial investor to scale-up and commercialize our bio-based chemical process technologies," said Robert Wedinger, President and CEO of Rennovia. "ADM's position as a leading producer of refined carbohydrates, combined with their focus on bio-based chemicals production, make them an ideal investor for Rennovia."

Source:

Archer Daniels Midland Company

Posted in: Business / Finance

Tags:

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post